

Neola Medical to Participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco

Neola Medical AB (publ) is pleased to announce its participation in the 43rd Annual J.P. Morgan Healthcare Conference, set to take place January 13–16, 2025, in San Francisco, California. The event, recognized as the premier global healthcare investment symposium, provides an unparalleled platform for connecting with industry leaders, innovative companies, and investors shaping the future of Life Sciences.

CEO Hanna Sjöström will attend to engage with investors and potential industry partners, focusing on the company's preparations for the anticipated U.S. market launch of Neola®, its advanced continuous lung monitoring device designed to improve care for preterm born babies in neonatal intensive care units.

"The J.P. Morgan Healthcare Conference offers an invaluable opportunity to strengthen Neola Medical's position as we advance toward commercialization. This event allows us to showcase our progress, forge meaningful partnerships, and align with key stakeholders who are essential to our U.S. market entry and scaling efforts." says Hanna Sjöström, CEO of Neola Medical.

As Neola Medical prepares for FDA approval, the company is actively laying the foundation for successful commercialization in the U.S. This includes strategic efforts to demonstrate the technology's value in clinical settings, build a strong sales presence, and establish effective market entry channels to support future growth.

For more information about the J.P. Morgan Healthcare Conference: <https://www.jpmorgan.com/solutions/cib/insights/health-care-conference>

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

[Neola Medical to Participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco](#)